10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
US biopharma AbbVie today announced that the Phase III VIALE-A trial of (venetoclax) in combination with azacitidine versus azacitidine in combination with placebo met its dual primary endpoints. 23 March 2020
As shares are falling around the world due to the coronavirus pandemic, those of Swiss clinical-stage biotech firm AC Immune were up 14.14% at $5.41 by mid-morning, after the company updated on its collaboration with Eli Lilly 23 March 2020
Germany’s Bayer and Indian drug discovery firm Curadev Pvt Ltd today announced a research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program. 23 March 2020
Initial data from a trial run by Oxford University spinout Vaccitech, together with the University of Oxford, show positive results for cancer candidate VTP-800. 23 March 2020
UK biotech Synairgen saw its share leap more than 52% to 49.00 pence by close of trading on Friday, after it revealed it has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a Phase II trial of its lead product SNG001 (inhaled interferon-beta-1a) in coronavirus (COVID-19) patients. 21 March 2020
Clinical-stage biotech Tarveda Therapeutics and China-owned SciClone Pharmaceuticals have entered into a licensing agreement for PEN-866, the initial clinical program from Tarveda’s HSP90 binding miniature drug conjugate platform. 20 March 2020
The UK BioIndustry Association (BIA) has welcomed revised proposals put forward by the government to ensure that genuine biotech companies are not penalised by a cap on R&D tax credits. 20 March 2020
The US Food and Drug Administration yesterday approved a supplemental application for Epclusa (sofosbuvir and velpatasvir) to treat hepatitis C virus (HCV) in children aged six years and older or weighing at least 37 pounds (17 kilograms) with any of the six HCV genotypes—or strains—without cirrhosis (liver disease) or with mild cirrhosis. 20 March 2020
A US court in Delaware has ruled in favor of Oxford Nanopore Technologies, in patent litigation between the UK biotech and California’s Pacific Biosciences (PacBio). 19 March 2020
US biotech firm Dragonfly Therapeutics today announced an expansion of its strategic collaboration with Merck & Co to discover, develop and commercialize a number of Dragonfly's candidate natural killer (NK) cell engager immunotherapies for oncology, infectious disease, and immune disorders. 19 March 2020
China’s National Medical Products Administration (NMPA) has granted marketing authorization for Ameile (almonertinib, previously also known as HS-10296) once daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after other EGFR tyrosine kinase inhibitor (TKI) therapy. 19 March 2020
As many drugmakers are looking at repurposing existing drugs to help alleviate the coronavirus crisis, Swiss pharma giant Roche says it is in talks with the US medicines regulator for its blockbuster immunosuppressive drug. 19 March 2020
With evidence from Chinese authorities suggesting that Avigan (favipiravir) could be effective in treating the symptoms of COVID-19, shares in the drug’s developer, Fujifilm Toyama Chemical, have surged. 19 March 2020
Switzerland-incorporated Roivant Sciences says it is engaged with regulators in the USA, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment of acute respiratory distress syndrome (ARDS) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 19 March 2020
Impact BioMedical has said that computational models indicate that its Linebacker and Equivir compounds successfully inhibit infection by SARS-CoV-2, the virus responsible for the COVID-19 outbreak. 18 March 2020
A tidal wave of media speculation involving small German mRNA-based drug specialist CureVac and its management changes, the coronavirus and US President Donald Trump, led the company to hold a media call on Tuesday evening as it could not respond to all the individual reporter inquiries. 18 March 2020